The relevance of DR3 expression in CLL is confirmed by the presence, in the sera from CLL patients, of its unique ligand TL1A that, similarly to DR3 expression, is more frequently detected in CLL patients at an early-stage disease. The gene discussed is TNFRSF25; the disease is B-cell chronic lymphocytic leukemia.